Risk of liver cancer from hepatitis B persists even after clearing the virus
Long-term infection with hepatitis B virus (HBV) can cause liver inflammation and increase the risk of liver cancer. Researchers from the US Centers for Disease Control and Prevention, however, found that resolving HBV infection was not associated with reduced rates of liver cancer.
A total of 238 patients who resolved HBV infection and 435 patients who did not were selected from among 1346 patients with chronic HBV infection followed for up to 31 years. The liver cancer risk, measured as a hazard ratio (HR), in patients after resolving HBV infection was similar compared with the risk in patients who did not resolve infection (HR: 0.7; 95% confidence interval: 0.2-2.4).
"Since the risk of liver cancer persists among adults with apparent cure of the infection, they might still need to be followed closely," said Dr. Prabhu Gounder, lead author of the Alimentary Pharmacology & Therapeutics article.作者: zgct 时间: 2016-4-24 07:10
RESULTS: The 238 case-patients (4 with HCC) and 435 control-patients (9 with HCC)
1982-2013 28年的追踪研究中,238名S清除患者中4人肝癌,435名S未清除患者中9人肝癌
J Clin Gastroenterol. 2011 Jan;45(1):64-8. doi: 10.1097/MCG.0b013e3181dd558c.
HBsAg seroclearance in chronic hepatitis B: implications for hepatocellular carcinoma.
Kim JH1, Lee YS, Lee HJ, Yoon E, Jung YK, Jong ES, Lee BJ, Seo YS, Yim HJ, Yeon JE, Park JJ, Kim JS, Bak YT, Byun KS.
Author information
Abstract
GOALS AND BACKGROUND:
The long-term clinical course, including the development of hepatocellular carcinoma (HCC) after hepatic B surface antigen (HBsAg) seroclearance is not established. We discovered that the incidence of HCC and the risk factors for HCC in chronic hepatitis B (CHB) patients after HBsAg seroclearance.
STUDY:
During 28 years, 96 CHB patients with HBsAg seroclearance were retrospectively reviewed. These patients continued to undergo HCC surveillance. The median follow-up time from initial visit was 166.5 months (range, 7 to 321 mo).
RESULTS:
The mean age at the initial visit and at the time of seroclearance was 39.2 ± 10.6 years and 46.4 ± 9.9 years, respectively. The mean age at the time of HBsAg seroclearance was significantly lower (P=0.03) in patients with spontaneous HBsAg seroclearance than patients with treatment-associated HBsAg seroclearance. During a median of 56 months (range, 7 to 238 mo) of follow-up after HBsAg seroclearance, 6 (6.5%) patients developed HCC. The mean age at the time of developing HCC was 55.8 ± 10.3 years. On univariate analysis, the evidence of liver cirrhosis from the time of HBsAg seroclearance and age more than 45 years at the time of HBsAg seroclearance were significant risk factors for HCC development. In multivariate analysis, the evidence of liver cirrhosis at HBsAg seroclearance was the only significant risk factor for HCC development.
CONCLUSIONS:
HCC can develop after HBsAg seroclearance in patients with known cirrhosis. Patients who achieved HBsAg seroclearance at older age (>45) may have undiagnosed cirrhosis and hence remain at risk for HCC. HCC surveillance should be carried out for both of those patient populations. http://onlinelibrary.wiley.com/doi/10.1111/apt.13621/abstract https://www.ncbi.nlm.nih.gov/pubmed/20535028作者: bigben446 时间: 2016-4-24 19:44
bigben446 发表于 2016-4-24 19:42
RESULTS:
The 238 case-patients (4 with HCC) and 435 control-patients (9 with HCC)
1982-2013 28年的追 ...
we could not adjust for several important HCC risk factors in our model comparing the HCC rate between case- and control-patients.
our results based on the AN population might not be generalisable to other populations.